The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Inefficacy of infliximab in primary Sjögren's syndrome: Results of the randomized, controlled trial of remicade in primary Sjögren's syndrome (TRIPSS)
Abstract
Objective: There is no effective treatment for patients with primary Sjögren's syndrome (SS). Since tumor necrosis factor α (TNFα) could be a key element in the pathogenesis of primary SS, we conducted a multicenter, randomized, double‐blind, placebo‐controlled trial to evaluate the effect of infliximab in primary SS. Methods: A total of 103 patients with primary SS were randomly assigned to receive infliximab infusions (5 mg/kg) or placebo at weeks 0, 2, and 6 and were followed up for 22 weeks. All patients fulfilled the new American‐European Consensus Group criteria for SS and had active disease as assessed by values >50 mm on 2 of 3 visual analog scales (VAS) (0–100 mm) that evaluated joint pain, fatigue, and buccal, ocular, skin, vaginal, or bronchial dryness. A favorable overall response was defined as the patient having ≥30% improvement between weeks 0 and 10 in the values on 2 of the 3 VAS. Secondary end points were values on each VAS separately, the number of tender and swollen joints, the basal salivary flow rate, results of the Schirmer test for lacrimal gland function, the focus score on labial salivary gland biopsy, the level of C‐reactive protein, and the erythrocyte sedimentation rate evaluated at weeks 0, 10, and 22, as well as quality of life evaluated by use of the generic Short Form 36 questionnaire administered at weeks 0, 10, and 22. Results: At week 10, 26.5% of patients receiving placebo and 27.8% of patients treated with infliximab had a favorable overall response (P = 0.89), and at week 22, 20.4% of the placebo group and 16.7% of the infliximab group had a favorable response (P = 0.62). In addition, the 2 groups did not differ in any of the secondary end points over the 22 weeks of the trial. Severe adverse events reported in the infliximab group did not differ from those observed in previous studies. Conclusion: This randomized, double‐blind, placebo‐controlled study of an anti‐TNF agent did not show any evidence of efficacy of infliximab in primary SS.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Vitali, C., Bombardieri, S., Jonsson, R., Moutsopoulos, H. M., Alexander, E. L., Carsons, S. E., Daniels, T. E., Fox, P. C., Fox, R. I., Kassan, S. S., et al. (2002) · Annals of the Rheumatic Diseases · doi:10.1136/ard.61.6.554 · Cited by 5,299
Randomized, Controlled Trials, Observational Studies, and the Hierarchy of Research Designs
Concato, J., Shah, N., & Horwitz, R. I. (2000) · New England Journal of Medicine · doi:10.1056/nejm200006223422507 · Cited by 3,563
Perneger, T. V., Leplège, A., Etter, J.-F., & Rougemont, A. (1995) · Journal of Clinical Epidemiology · doi:10.1016/0895-4356(94)00227-h · Cited by 314
Akin, R. K., Kreller, A. J., & Walters, P. J. (1975) · Plastic and Reconstructive Surgery · doi:10.1097/00006534-197510000-00031 · Cited by 240
PATHOGENESIS OF SJÖGREN’S SYNDROME
Fox, R. I., & Kang, H.-I. (1992) · Rheumatic Disease Clinics of North America · doi:10.1016/s0889-857x(21)00314-8 · Cited by 233
De Rycke, L., Kruithof, E., Van Damme, N., Hoffman, I. E. A., Van den Bossche, N., Van den Bosch, F., Veys, E. M., & De Keyser, F. (2003) · Arthritis & Rheumatism · doi:10.1002/art.10876 · Cited by 223
Capp Filho, P., Decker, W. G., & St, P. (1979) · PubMed · Cited by 189
Abel, U. R., & Koch, A. (1999) · Journal of Clinical Epidemiology · doi:10.1016/s0895-4356(99)00041-4 · Cited by 132
Haddad, E., Rousell, J., Lindsay, M. A., & Barnes, P. J. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.51.32586 · Cited by 60
Ho (2001) · Pure Amsterdam UMC · doi:10.1002/1529-0131(200110)44:10 · Cited by 3
Cited by
TFOS DEWS II Management and Therapy Report
Jones, L., Downie, L. E., Korb, D., Benitez-del-Castillo, J. M., Dana, R., Deng, S. X., Dong, P. N., Geerling, G., Hida, R. Y., Liu, Y., et al. (2017) · The Ocular Surface · doi:10.1016/j.jtos.2017.05.006 · Cited by 1,422
Seror, R., Ravaud, P., Bowman, S. J., Baron, G., Tzioufas, A., Theander, E., Gottenberg, J.-E., Bootsma, H., Mariette, X., & Vitali, C. (2010) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2009.110619 · Cited by 965
Self-citationMariette, X., & Criswell, L. A. (2018) · New England Journal of Medicine · doi:10.1056/nejmcp1702514 · Cited by 947
Self-citationAdverse effects of biologics: a network meta-analysis and Cochrane overview
Singh, J. A., Wells, G. A., Christensen, R., Tanjong Ghogomu, E., Maxwell, L. J., MacDonald, J. K., Filippini, G., Skoetz, N., Francis, D. K., Lopes, L. C., et al. (2011) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd008794.pub2 · Cited by 823
Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2010
Furst, D. E., Keystone, E. C., Braun, J., Breedveld, F. C., Burmester, G. R., De Benedetti, F., Dörner, T., Emery, P., Fleischmann, R., Gibofsky, A., et al. (2011) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2010.146852 · Cited by 687
Metadata
- Authors
- Mariette, X., Ravaud, P., Steinfeld, S., Baron, G., Goetz, J., Hachulla, E., Combe, B., Puéchal, X., Pennec, Y., Sauvezie, B., Perdriger, A., Hayem, G., Janin, A., & Sibilia, J.
- Venue
- Arthritis & Rheumatism
- Publisher
- Wiley
- Published
- 2004-04
- Volume
- 50
- Issue
- 4
- Pages
- 1270-1276
- ISSN
- 0004-3591 (ISSN-L)
- 1529-0131
- OpenAlex
- W2059189040
- Cited by
- 437
- References
- 10
- FWCI
- 15.01
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Inefficacy of infliximab in primary Sjögren's syndrome: Results of the randomized, controlled trial of remicade in primary Sjögren's syndrome (TRIPSS). https://app.cochat.ai/papers/10.1002/art.20146
- The paper
- Mariette, X., Ravaud, P., Steinfeld, S., Baron, G., Goetz, J., Hachulla, E., Combe, B., Puéchal, X., Pennec, Y., Sauvezie, B., Perdriger, A., Hayem, G., Janin, A., & Sibilia, J. (2004). Inefficacy of infliximab in primary Sjögren's syndrome: Results of the randomized, controlled trial of remicade in primary Sjögren's syndrome (TRIPSS). Arthritis & Rheumatism. https://doi.org/10.1002/art.20146
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.